Semaglutide Liraglutide Lyophilized Peptides 10mg/Vails In Stock

Lyophilized Peptides Semaglutide Liraglutide 10mg/Vails in Stock

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes. It has become popular because of its outstanding weight loss effect, and was approved by FDA to be marketed as a weight loss drug in June 2022.
In recent years, studies on semaglutide have emerged in endlessly. It has been found that in addition to treating type 2 diabetes and losing weight, smeglutide has many health benefits. For example, Senaglutide can restore the function of NK cells in the body, including its ability to kill cancer cells, thereby reducing the risk of cancer; It can reduce liver enzyme levels and has the potential to treat non-alcoholic fatty liver disease; It can significantly reduce the risk of cardiovascular disease; It can even help quit smoking and alcohol.
Recently, the research team of the State University of New York at Buffalo found that semaglutide also has the potential to treat early type 1 diabetes.